Stephen A. Sherwin's most recent trade in Biogen Inc was a trade of 2,370 Common Stock done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 2,370 | 13,688 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,318 | 3,318 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 2,869 | 13,542 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 2,869 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Stephen A. Sherwin | Director | Sale of securities on an exchange or to another person at price $ 150.02 per share. | 07 Mar 2025 | 8,760 | 11,318 (0%) | 0% | 150.0 | 1,314,142 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Sale of securities on an exchange or to another person at price $ 116.69 per share. | 13 Feb 2025 | 13,831 | 10,673 (0%) | 0% | 116.7 | 1,613,923 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Nov 2024 | 2,000 | 24,504 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 1,340 | 20,078 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 25,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Sale of securities on an exchange or to another person at price $ 133.46 per share. | 29 May 2024 | 25,000 | 26,504 (0%) | 0% | 133.5 | 3,336,555 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.76 per share. | 29 May 2024 | 25,000 | 51,504 (0%) | 0% | 42.8 | 1,069,000 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Sale of securities on an exchange or to another person at price $ 133.47 per share. | 29 May 2024 | 15,000 | 26,504 (0%) | 0% | 133.5 | 2,002,010 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.89 per share. | 29 May 2024 | 15,000 | 41,504 (0%) | 0% | 47.9 | 718,350 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2024 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,869 | 2,869 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 4,199 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 4,199 | 26,504 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2023 | 960 | 18,738 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,199 | 4,199 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Sale of securities on an exchange or to another person at price $ 118.85 per share. | 03 Jan 2023 | 15,000 | 25,055 (0%) | 0% | 118.9 | 1,782,752 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 03 Jan 2023 | 15,000 | 40,055 (0%) | 0% | 13.0 | 194,700 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Sale of securities on an exchange or to another person at price $ 118.87 per share. | 03 Jan 2023 | 15,000 | 25,055 (0%) | 0% | 118.9 | 1,782,977 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.71 per share. | 03 Jan 2023 | 15,000 | 40,055 (0%) | 0% | 12.7 | 190,650 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Biogen Inc | Stephen A. Sherwin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 695 | 17,778 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 1,370 | 18,473 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 9,724 | 9,724 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.66 per share. | 24 Jan 2022 | 15,000 | 40,055 (0%) | 0% | 6.7 | 99,900 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2022 | 15,000 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Sale of securities on an exchange or to another person at price $ 74.43 per share. | 24 Jan 2022 | 15,000 | 25,055 (0%) | 0% | 74.4 | 1,116,378 | Common Stock |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 2,000 | 25,055 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 775 | 17,103 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 8,833 | 8,833 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Stephen A. Sherwin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Dec 2020 | 2,806 | 27,055 (0%) | 0% | 0 | Common Stock |